Annual FCF
-$272.35 M
+$260.58 M+48.90%
31 December 2023
Summary:
CRISPR Therapeutics AG annual free cash flow is currently -$272.35 million, with the most recent change of +$260.58 million (+48.90%) on 31 December 2023. During the last 3 years, it has fallen by -$15.62 million (-6.08%). CRSP annual FCF is now -159.56% below its all-time high of $457.27 million, reached on 31 December 2021.CRSP Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$107.13 M
-$10.84 M-11.26%
30 September 2024
Summary:
CRISPR Therapeutics AG quarterly free cash flow is currently -$107.13 million, with the most recent change of -$10.84 million (-11.26%) on 30 September 2024. Over the past year, it has dropped by -$64.16 million (-149.29%). CRSP quarterly FCF is now -113.76% below its all-time high of $778.55 million, reached on 30 June 2021.CRSP Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$191.20 M
-$64.16 M-50.50%
30 September 2024
Summary:
CRISPR Therapeutics AG TTM free cash flow is currently -$191.20 million, with the most recent change of -$64.16 million (-50.50%) on 30 September 2024. Over the past year, it has increased by +$103.85 million (+35.20%). CRSP TTM FCF is now -138.07% below its all-time high of $502.19 million, reached on 30 June 2021.CRSP TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRSP Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +48.9% | -149.3% | +35.2% |
| 3 y3 years | -6.1% | +9.5% | -141.1% |
| 5 y5 years | -175.1% | -181.8% | -1150.7% |
CRSP Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -159.6% | +48.9% | -198.3% | +29.3% | -141.1% | +64.1% |
| 5 y | 5 years | -159.6% | +48.9% | -113.8% | +29.3% | -138.1% | +64.1% |
| alltime | all time | -159.6% | +48.9% | -113.8% | +29.3% | -138.1% | +64.1% |
CRISPR Therapeutics AG Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$107.13 M(+11.3%) | -$191.20 M(+50.5%) |
| June 2024 | - | -$96.29 M(-188.3%) | -$127.04 M(-24.9%) |
| Mar 2024 | - | $109.03 M(-212.6%) | -$169.05 M(-37.9%) |
| Dec 2023 | -$272.35 M(-48.9%) | -$96.81 M(+125.3%) | -$272.35 M(-7.7%) |
| Sept 2023 | - | -$42.97 M(-68.9%) | -$295.05 M(-18.8%) |
| June 2023 | - | -$138.30 M(-2509.4%) | -$363.31 M(-3.5%) |
| Mar 2023 | - | $5.74 M(-104.8%) | -$376.60 M(-29.3%) |
| Dec 2022 | -$532.93 M(-216.5%) | -$119.52 M(+7.4%) | -$532.93 M(+4.8%) |
| Sept 2022 | - | -$111.23 M(-26.6%) | -$508.63 M(-1.4%) |
| June 2022 | - | -$151.59 M(+0.7%) | -$515.77 M(-224.5%) |
| Mar 2022 | - | -$150.59 M(+58.1%) | $414.37 M(-9.4%) |
| Dec 2021 | $457.27 M(-278.1%) | -$95.22 M(-19.6%) | $457.27 M(-1.7%) |
| Sept 2021 | - | -$118.38 M(-115.2%) | $465.04 M(-7.4%) |
| June 2021 | - | $778.55 M(-823.0%) | $502.19 M(-262.4%) |
| Mar 2021 | - | -$107.69 M(+23.1%) | -$309.25 M(+20.5%) |
| Dec 2020 | -$256.72 M | -$87.45 M(+7.7%) | -$256.72 M(+53.9%) |
| Sept 2020 | - | -$81.22 M(+147.0%) | -$166.85 M(-468.1%) |
| June 2020 | - | -$32.88 M(-40.4%) | $45.33 M(+14.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$55.17 M(-2375.8%) | $39.66 M(-20.7%) |
| Dec 2019 | $49.99 M(-150.5%) | $2.42 M(-98.1%) | $49.99 M(+174.7%) |
| Sept 2019 | - | $130.96 M(-439.7%) | $18.20 M(-113.6%) |
| June 2019 | - | -$38.56 M(-14.0%) | -$133.42 M(+10.6%) |
| Mar 2019 | - | -$44.83 M(+52.6%) | -$120.60 M(+21.8%) |
| Dec 2018 | -$99.01 M(+27.1%) | -$29.37 M(+42.2%) | -$99.01 M(+16.9%) |
| Sept 2018 | - | -$20.66 M(-19.7%) | -$84.69 M(+2.2%) |
| June 2018 | - | -$25.74 M(+10.7%) | -$82.89 M(+11.3%) |
| Mar 2018 | - | -$23.24 M(+54.5%) | -$74.45 M(-4.4%) |
| Dec 2017 | -$77.91 M(+39.4%) | -$15.05 M(-20.2%) | -$77.91 M(-2.7%) |
| Sept 2017 | - | -$18.86 M(+9.0%) | -$80.05 M(+6.8%) |
| June 2017 | - | -$17.30 M(-35.2%) | -$74.98 M(+3.7%) |
| Mar 2017 | - | -$26.70 M(+55.3%) | -$72.33 M(+29.4%) |
| Dec 2016 | -$55.88 M(-195.9%) | -$17.19 M(+24.7%) | -$55.88 M(+44.4%) |
| Sept 2016 | - | -$13.79 M(-5.9%) | -$38.68 M(+55.4%) |
| June 2016 | - | -$14.65 M(+43.0%) | -$24.90 M(+143.0%) |
| Mar 2016 | - | -$10.25 M | -$10.25 M |
| Dec 2015 | $58.27 M(-1315.8%) | - | - |
| Dec 2014 | -$4.79 M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual free cash flow?
- What is the all time high annual FCF for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual FCF year-on-year change?
- What is CRISPR Therapeutics AG quarterly free cash flow?
- What is the all time high quarterly FCF for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly FCF year-on-year change?
- What is CRISPR Therapeutics AG TTM free cash flow?
- What is the all time high TTM FCF for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM FCF year-on-year change?
What is CRISPR Therapeutics AG annual free cash flow?
The current annual FCF of CRSP is -$272.35 M
What is the all time high annual FCF for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual free cash flow is $457.27 M
What is CRISPR Therapeutics AG annual FCF year-on-year change?
Over the past year, CRSP annual free cash flow has changed by +$260.58 M (+48.90%)
What is CRISPR Therapeutics AG quarterly free cash flow?
The current quarterly FCF of CRSP is -$107.13 M
What is the all time high quarterly FCF for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly free cash flow is $778.55 M
What is CRISPR Therapeutics AG quarterly FCF year-on-year change?
Over the past year, CRSP quarterly free cash flow has changed by -$64.16 M (-149.29%)
What is CRISPR Therapeutics AG TTM free cash flow?
The current TTM FCF of CRSP is -$191.20 M
What is the all time high TTM FCF for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM free cash flow is $502.19 M
What is CRISPR Therapeutics AG TTM FCF year-on-year change?
Over the past year, CRSP TTM free cash flow has changed by +$103.85 M (+35.20%)